Talimogene laherparepvec

Drug Profile

Talimogene laherparepvec

Alternative Names: IMLYGIC; JS1/34.5- /47-/GM-CSF; OncoVEX; OncoVEXGM-CSF; T-VEC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Merck & Co; University of Iowa
  • Class Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Soft tissue sarcoma
  • Phase I Head and neck cancer; Liver cancer
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 26 Oct 2017 Discontinued - Phase-III for Head and neck cancer (Combination therapy, First-line therapy) in USA, United Kingdom (Intratumoural) (Amgen pipeline, October 2017)
  • 13 Oct 2017 Amgen initiates enrolment in a phase I trial in Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural) (NCT03086642)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top